PFEPfizer Inc.
AI adoption · Q1 2026 earnings call
Health CarePiloting
3
extracted from this call
2 / 5
directional only
Not disclosed
no breakout in this call
AI was mentioned briefly in CEO Albert Bourla's prepared remarks as a 'key strategic priority' embedded across R&D, commercial, manufacturing, and enterprise functions. The commentary was high-level and aspirational, framing AI as a tool to compress timelines and improve decision-making in drug discovery and development. No quantification of AI investment, productivity gains, or revenue impact was provided, and no analyst questions addressed AI directly.
Adopter
See full leaderboard →27/ 100
49
stage: piloting · max spec: 2
0
no quantified disclosure
35
1 scope
internal_use
3 AI mentions from this call.
Extracted verbatim from the PFE Q1 2026 earnings call transcript. Speaker, section, and specificity tier surfaced for each mention.
- T2Prepared remarks· CEO· Internal use
“One of the areas where we see the most substantial promise is the discovery, development and delivery of new medicines and vaccines. Leveraging the power of AI to compress timelines and improve decision-making is central to our innovation strategy. We are embedding AI into each functional line of R&D. Pfizer has a vast repository of small and large molecule, translational and clinical data and AI is creating the opportunity to unlock insights that could drive a significant impact on how we discover and develop medicines and vaccines.”
— Albert Bourla, PFE earnings call - T2Prepared remarks· CEO· Internal use
“Embedding the use of artificial intelligence across our company is a key strategic priority, and we are driving continued progress in R&D, commercial, manufacturing and core enterprise functions. We are empowering our colleagues to accelerate innovation by pairing frontier AI tools, tailored to function and role, with comprehensive and continuously updated training.”
— Albert Bourla, PFE earnings call - T1Q&A· CEO· Internal usewhat's the likelihood that Pfizer entertains a transformative M&A in near or medium term, which could end up impacting dividend as we've seen in history?
“we think that right now, in the next few years, it is the time to execute on AI transformation of these organizations. And that requires not the disruption of mega merger.”
— Albert Bourla, PFE earnings call
What management wouldn’t quantify.
Analyst questions where management declined to share a specific number. The pattern of refusals is often as informative as the disclosures.
- No quantification of AI investment (capex or opex) was provided.
- No metrics on AI adoption, productivity gains, or headcount impact were disclosed.
- No AI revenue attribution or contribution to pipeline acceleration was quantified.
- No specific AI products, platforms, or vendor partnerships were named.
- No analyst questions were asked about AI, and management did not volunteer further detail beyond the prepared remarks passage.
- The reference to 'frontier AI tools' and 'comprehensive training' lacked any specifics on which tools, how many employees, or what outcomes have been measured.
Compare with peers.
Other companies in the same sector and at the same AI adoption stage.
Same GICS sector, all stages
Independent research, direct to your inbox.
Live data tracking and analysis. Deep research that cuts through consensus. Evidence-backed insights.